Compare Amphastar Pharmaceuticals Inc (AMPH) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Atlassian Corporation PLC — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Atlassian Corporation PLC trades at $90.1 (market cap $22.55B). The key difference: Atlassian Corporation PLC is far larger — about 27.3× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | TEAM | |
|---|---|---|
Market Cap | $826.08M | $22.55B |
Sector | Health | Technology |
52-Week High | $30.81 | $203.00 |
52-Week Low | $16.87 | $57.15 |
Enterprise Value | $1.22B | $22.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Atlassian (TEAM) trades at $88.86, down 2.04% today, with strong technical momentum indicated by bullish moving averages. The company shows accelerating revenue growth reaching $5.22B in 2025, though it remains unprofitable with a -3.5% net margin. Recent earnings beats and cloud revenue growth of 29% in Q3 FY26 demonstrate business momentum, while analyst consensus remains strongly bullish with a $119.93 price target representing 35% upside potential.
TEAM presents a compelling growth story with improving fundamentals and strong analyst support, though profitability challenges and AI disruption risks require monitoring. The stock's current valuation at 3.77x sales appears reasonable given the 30%+ revenue growth trajectory, making it attractive for growth-oriented investors willing to accept near-term losses for long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
